Next Article in Journal
Effect of Acceptor and Donor Substituents in the ortho, meta, and para Positions in the Nitrobenzene Molecule on the Reaction of Interaction with Ethylene
Previous Article in Journal
Open Bottom Production in Au Au Collisions at √sNN = 200 GeV with the STAR Experiment
Article Menu
Issue 1 (CA16112 - Luxemburg 2019) cover image

Export Article

Open AccessAbstract

Cytoprotective and Antioxidants in Peroxisomal Neurodegenerative Diseases

NutRedOx Network (COST Action CA16112), 1050 Brussels, Belgium
BioPeroxIL laboratory, Université de Bourgogne-Franche Comté, 6, Boulevard Gabriel, 21000 Dijon, France
Organic Chemistry Division, Department of Chemistry, Faculty of Science, Mansoura University, El-Gomhorya Street, 35516 Mansoura, Egypt
Institute of Organic Chemistry and Chemical Biology, Goethe-University Frankfurt, Max-von-Laue-Str. 7, 60438 Frankfurt/Main, Germany
Laboratoire de Biochimie et Neurosciences, Faculté des Sciences et Techniques, Université Hassan I, BP577, 26000 Settat, Morocco
Botany Department, Faculty of Science, Mansoura University, 35516 Mansoura, Egypt
Institut de Chimie Moléculaire de l’Université de Bourgogne-Franche Comté, UMR6302, CNRS, Université Bourgogne Franche Comté, F-21000 Dijon, France
Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B2 1, D-66123 Saarbuecken, Germany
Author to whom correspondence should be addressed.
Presented at the Natural Products and the Hallmarks of Chronic Diseases—COST Action 16112, Luxemburg, 25–27 March 2019.
Proceedings 2019, 11(1), 33;
Published: 28 April 2019
PDF [176 KB, uploaded 28 April 2019]


Several of the peroxisomal neurodegenerative disorders are the consequence of a specific deficiency of an enzyme or a transporter involved in peroxisomal beta-oxidation of very long chain fatty acids [1,2]. One of the hallmarks in these peroxisomal rare neurodegenerative diseases and in other common demyelinating disorders is the accompanying oxidative damage and neuroinflammation [3]. Compelling data indicates that oxidative stress can activate microglia leading to the overproduction of pro-inflammatory molecules [4,5]. Thus, targeting oxidative stress to limit neuroinflammation may open a new pharmacological therapy window for these still incurable devastating peroxisomal diseases. Here, we present different natural (resveratrol) [6] and synthetic (organoselenides) [7] antioxidant compounds for their capacity of scavenging oxidative stress and in the perspective therapeutic use against oxidative damage in peroxisomal disorders.
Keywords: antioxidant; leukodystrophy; organoselenides; peroxisome; resveratrol antioxidant; leukodystrophy; organoselenides; peroxisome; resveratrol
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Cherkaoui-Malki, M.; Shaaban, S.; Tahri-Joutey, M.; Elshobaky, A.; Saih, F.-E.; Vervandier-Fasseur, D.; Jacob, C.; Nasser, B.; Latruffe, N.; Andreoletti, P. Cytoprotective and Antioxidants in Peroxisomal Neurodegenerative Diseases. Proceedings 2019, 11, 33.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics



[Return to top]
Proceedings EISSN 2504-3900 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top